Welcome New and Upgraded Corporate Partners, March 2021

Please join us in welcoming the following companies new to HBA corporate partnership in 2021:


Kite, a Gilead Company
CEO: Christi Shaw
Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California, with commercial manufacturing operations in North America and Europe. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. For more information on Kite, please visit www.kitepharma.com.

CEO: Stephen J. Ubl
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. In 2019, PhRMA members invested an estimated $83 billion searching for new treatments and cures.


Daiichi Sankyo Europe GmbH
Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products with a clear focus on patients’ needs. In Europe, we concentrate on two areas: our cardiovascular portfolio reflects our long-standing commitment and shows that we care for every heartbeat; in oncology, we aim to become a “Global Pharma Innovator with a Competitive Advantage in Oncology.” 


CEO: Stan Woodland
For over 30 years Compas has been partnering with the industry’s leading media providers, as well as up-and-coming innovators – representing all channels and tactics – positioning them for success with healthcare clients and agencies. As stewards of our clients’ media investments, Compas is committed to enforcing the highest standards of buying execution, effectiveness, transparency and accountability while leveraging our clients’ collective buying power through a consortium that unlocks incremental savings. Compas is certified by the National Minority Supplier Diversity Council as a minority-owned-and-operated business and generates significant Tier 1 and Tier 2 Diverse Spend.

Ferring Canada
General manager: Lee Ferreira
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

Zymeworks Inc. 
CEO: Ali Tehrani, PhD
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody that has been granted Breakthrough Therapy designation by the FDA and targets HER2-expressing cancers. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development. In addition, Zymeworks is advancing a deep preclinical pipeline in oncology and other therapeutic areas, and the Company’s therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.



Acadia Pharmaceuticals Inc.
CEO: Stephen R. Davis
Acadia is trailblazing breakthroughs in neuroscience to elevate life. We are at the forefront of healthcare, fighting for breakthroughs in our science, our therapies and the way we work, but also in the lives of the people we serve.

Morphic Therapeutic
CEO: Praveen Tipirneni
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases such as autoimmune and fibrosis. Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology.


We would also like to recognize these corporate partners increasing their commitment to being a United Force for Change with higher-level partnerships in 2021: